The reported clinical benefits of combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors for NSCLC with STK11 and/or KEAP1 mutations are based on exploratory analyses of phase III clinical trials and involve unstratified univariate analysis with a relatively smaller sample size. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.